The Latest Breaking News from Chemotherapy

Tracey Ferrin, 39, from Texas in the US, was pregnant with her second child and going through gruelling cancer treatment when her marriage broke down - but years on, she doesn't hold any resentment towards him

The FDA has accepted AstraZeneca plc’s (NASDAQ) supplemental marketing application seeking approval for Imfinzi (durvalumab), in combination with standard-of-care chemotherapy, for locally advanced or metastatic biliary tract cancer (BTC). Under the Priority Review status, the FDA action date is during the third quarter of 2022. BTC is a group of rare and aggressive…

Galera Therapeutics Inc (NASDAQ:GRTX) announced topline results from Phase 2a AESOP trial of avasopasem for severe acute radiation-induced esophagitis in lung cancer patients receiving concurrent chemoradiotherapy. Esophagitis is an early side effect of radiation or chemoradiation, causing pain, difficulties in swallowing with potential malnutrition, and dehydration. The trial enrolled 39 patients with unresectable…

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

Lindsey Parry, a 46-year-old from Scarborough, Yorkshire, had a number of small lumps and itchy skin and thought it was just symptoms for glandular fever but it turned out to be a form of cancer

The French authority has signed off XBiotech Inc's (NASDAQ:XBIT) multicenter randomized clinical study for Natrunix combined with trifluridine/tipiracil for colorectal cancer.  The French National Cancer Institute (INCA) has also awarded a grant to fund all clinical costs for the study. Investigators will combine Natrunix and trifluridine/tipiracil as a new candidate therapy for metastatic…

Statera Biopharma Inc (NASDAQ:STAB) has entered into a non-binding term sheet with Immune Therapeutics Inc (OTC:IMUN) to sell its naltrexone and met-enkephalin rights. The transaction is contingent upon the negotiation of a definitive agreement and satisfaction of several closing conditions, including a contingency on Immune Therapeutics financing. Under the anticipated terms, Statera will receive an…

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

Here's a roundup of top developments in the biotech space over the last 24 hours.

Quantum Leap Healthcare Collaborative and Ambrx Biopharma Inc (NYSE:AMAM) have announced the selection of Ambrx's antibody-drug conjugate (ADC) ARX788 for a new investigational treatment arm in the I-SPY 2.2 TRIAL. Sponsored by Quantum Leap, I-SPY 2.2 is an adaptive Phase 2 trial that evaluates emerging targeted agents, allowing those agents to either be combined…